A prospective evaluation of chronic Babesia microti infection in seroreactive blood donors

Transfusion

Volumn 56, Issue 7, 2016, Pages 1875-1882

  Bloch, Evan M ^a,b   Levin, Andrew E ^c   Williamson, Phillip C ^d   Cyrus, Sherri ^d   Shaz, Beth H ^e   Kessler, Debra ^e   Gorlin, Jed ^f   Bruhn, Roberta ^b   Lee, Tzong Hae ^b   Montalvo, Leilani ^b   Kamel, Hany ^g   Busch, Michael P ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c IMMUNETICS INC   (United States)

^d CREATIVE TESTING SOLUTIONS   (United States)

^e NEW YORK BLOOD CENTER   (United States)

^f Innovative Blood Resources Memorial Blood Center   (United States)

^g Blood Systems Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APICOMPLEXAN INFECTION; ARTICLE; BABESIA MICROTI; BABESIA MICROTI INFECTION; BLOOD DONOR; BLOOD SMEAR; COHORT ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY;

EID: 84977630068     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13617     Document Type: Article

References (25)

1. Gubernot DM, Lucey CT, Lee KC, et al. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009;48:25–30.
2. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2014. Silver Spring (MD): US Food and Drug Administration; 2014.
3. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. Silver Spring (MD): US Food and Drug Administration; 2013.
4. Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011;155:509–19.
5. Levin AE, Williamson PC, Erwin JL, et al. Determination of Babesia microti seroprevalence in blood donor populations using an investigational enzyme immunoassay. Transfusion 2014;54:2237–44.
6. Moritz ED, Winton CS, Johnson ST, et al. Investigational screening for Babesia microti in a large repository of blood donor samples from nonendemic and endemic areas of the United States. Transfusion 2014;54:2226–36.
7. Goodell AJ, Bloch EM, Krause PJ, et al. Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply. Transfusion 2014;54:2245–57.
8. Leiby DA, Chung AP, Gill JE, et al. Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti. Transfusion 2005;45:1804–10.
9. Linden JV, Wong SJ, Chu FK, et al. Transfusion-associated transmission of babesiosis in New York State. Transfusion 2000;40:285–9.
10. Johnson ST, Cable RG, Leiby DA. Lookback investigations of Babesia microti-seropositive blood donors: seven-year experience in a Babesia-endemic area. Transfusion 2012;52:1509–16.
11. Ruebush TK 2nd, Juranek DD, Chisholm ES, et al. Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 1977;297:825–7.
12. Filstein MR, Benach JL, White DJ, et al. Serosurvey for human babesiosis in New York. J Infect Dis 1980;141:518–21.
13. Krause PJ, Telford SR 3rd, Pollack RJ, et al. Babesiosis: an underdiagnosed disease of children. Pediatrics 1992;89:1045–8.
14. Levin AE, Williamson PC, Bloch EM, et al. Serological screening of United States blood donors for Babesia microti using an investigational enzyme immunoassay. Transfusion 2016. In press.
15. Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998;339:160–5.
16. Leiby DA, Johnson ST, Won KY, et al. A longitudinal study of Babesia microti infection in seropositive blood donors. Transfusion 2014;54:2217–25.
17. Moritz E, Stramer S. Antibody and DNA duration in asymptomatic blood donors who screen positive in investigational testing for Babesia microti. Transfusion 2015;55:192A.
18. Leiby DA, Chung AP, Cable RG, et al. Relationship between tick bites and the seroprevalence of Babesia microti and Anaplasma phagocytophila (previously Ehrlichia sp.) in blood donors. Transfusion 2002;42:1585–91.
19. Parasites—babesiosis—epidemiology & risk factors. Atlanta (GA): Centers for Disease Control and Prevention; 2015.
20. Birkenheuer AJ, Correa MT, Levy MG, et al. Geographic distribution of babesiosis among dogs in the United States and association with dog bites: 150 cases (2000-2003). J Am Vet Med Assoc 2005;227:942–7.
21. Yancey CB, Hegarty BC, Qurollo BA, et al. Regional seroreactivity and vector-borne disease co-exposures in dogs in the United States from 2004-2010: utility of canine surveillance. Vector Borne Zoonotic Dis 2014;14:724–32.
22. May 13, 2015: Blood products advisory committee meeting summary minutes. Silver Spring (MD): US Food and Drug Administration; 2015.
23. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply—time to raise the bar. N Engl J Med 2015;372:1882–5.
24. Wang G, Villafuerte P, Zhuge J, et al. Comparison of a quantitative PCR assay with peripheral blood smear examination for detection and quantitation of Babesia microti infection in humans. Diagn Microbiol Infect Dis 2015;82:109–13.
25. Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012;52:1517–22.